Beam Therapeutics Inc. Stock Split Ratio
Beam Therapeutics Inc. (BEAM) reported Stock Split Ratio of 448.43% for the 1-month period ending 2020-01-31, per its 10-K filed 2021-03-15.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2021-03-15
- 2020-01-31: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 448.43%.
- 2020-01-24: Stockholders' Equity Note, Stock Split, Conversion Ratio 22.30%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|---|
| 2020-01-31 | 448.43% 10-K · filed 2021-03-15 | |
| 2020-01-24 | 22.30% 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |